The Glaxo gene therapy program will focus on a severe immunedeficiency called ADA-SCID, in which kids cannot make a crucial enzyme called adenosine deaminase that is needed to create immune system cells.
The findings, reported Sunday by researchers, mark only the second documented case of a patient being cured of infection with the human immune-deficiency virus.